---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-000870"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T02:59:11.153165+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ADMA prelim FY2024 rev $417-425M, guides FY2025 >$485M

## Summary
- FY2024 preliminary total revenue $417-425M, exceeding prior guidance of $415M; cash >$100M with $30M debt repaid in Q4.
- FY2025 revenue guided >$485M, net income >$170M, Adj EBITDA >$220M; FY2026 revenue >$600M, net income >$230M.
- PAS submitted to FDA for yield enhancement process that could increase IG yields ~20%; approval expected mid-2025.
- Executed long-term high titer plasma supply contracts from ~250 collection centers (5x increase) to support ASCENIV growth.
- Balance sheet: net cash surplus vs. $75M debt; expect >$1B annual revenue before 2030 with outsized earnings growth.

## SEC filing metadata
- accession: 0001140361-25-000870
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036125000870/0001140361-25-000870-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036125000870/ef20041448_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-000870
- JSON: https://secwatch.observer/filing/0001140361-25-000870.json
- Plain text: https://secwatch.observer/filing/0001140361-25-000870.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.